A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117 - Wikidata - awgldk - TriplyDB

A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117

A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117

http://www.wikidata.org/entity/Q33847603

about

Radiation dose effect in locally advanced non-small cell lung cancer Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer.Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer.Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.Human apurinic/apyrimidinic endonuclease siRNA inhibits the angiogenesis induced by X-ray irradiation in lung cancer cells.Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer.High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.The use of dose-escalated radiation for locally advanced non-small cell lung cancer in the U.S., 2004-2013.Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer.Therapeutic management options for stage III non-small cell lung cancer.Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions.Integrating stereotactic body radiation therapy in stage II/III non-small cell lung cancer: is local control important?Feasibility of image-guided radiotherapy and concurrent chemotherapy for locally advanced nonsmall cell lung cancer.Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer.What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review.Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).Clinical outcome of image-guided adaptive radiotherapy in the treatment of lung cancer patients.Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy.Accuracy of deformable image registration for contour propagation in adaptive lung radiotherapy.Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.Assessing margin expansions of internal target volumes in 3D and 4D PET: a phantom study.Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer.Impact of tumour motion compensation and delineation methods on FDG PET-based dose painting plan quality for NSCLC radiation therapy.Evaluation of adaptive treatment planning for patients with non-small cell lung cancer.Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? -a dosimetric evaluation of three different treatment plans.An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.Locally advanced non-small cell lung cancer treatment: another step forward.Selective nodal irradiation of regionally advanced non-small-cell lung cancer with proton therapy and IMRT: A dosimetric comparison.Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.

P2860

Q26823043-AD4EBC1A-2DBF-414A-B2BB-AAD143A6341D Q27027626-CB0E8BEF-929F-4947-B8CF-8FA924A2DB82 Q33402602-317A5778-74F1-409E-9267-78C9D73FED52 Q34298368-3CBA78AA-5A1C-4D9A-A292-B95DD055EBB2 Q35402102-692C291D-01E2-45BC-AEE4-A050489D8394 Q35568485-499D5E79-9B01-4F7B-83D4-C01AA8D046C0 Q35971034-F81BD132-C830-41F8-8348-709C7A4E1A6A Q36279626-C9B8F004-1712-4569-A9DA-D6679499DE50 Q36500052-544F0E7B-16CD-43C1-AB52-BD97026DA8E1 Q36729045-9ECACA4E-5DA3-4DB4-AAF8-59D9ECE1A659 Q36909832-8DFBDB48-145A-4BA8-ADEE-24FECA0A960F Q37037949-D9568EA1-9C92-4FD0-A77C-07BF48B572AE Q37114850-1D8A207C-6814-4ACE-8608-F696EBA3415E Q37152509-264784D9-D805-4818-9C4F-735297E7CE6E Q37589335-798004D4-8335-46E1-A363-254202DDD322 Q37633737-D4486773-3BC3-4FDC-A872-D76536D0AA77 Q37642455-2CEB7EB3-940D-44EA-9B17-E4E301A85879 Q37921958-FE9E1DA5-161D-45F8-9AC6-C18023FAA48F Q38243178-D1FD001E-BA17-4324-948E-D9F4A0C39A50 Q38337069-A3ABC4F4-6EF3-4389-93EF-0689EF45CC27 Q38549486-98980973-F317-4E95-BAA3-1A3A2BAD9116 Q38620687-5A2D6A16-ED46-4D55-9779-B97F418330EC Q38711723-DF1E5EC1-6201-42C6-8726-198E600E1EEB Q39019487-E2CC6A52-D2C0-407A-852D-EDD61B5B900A Q40701391-49A8C85D-09F6-4F91-956E-6FD49F106D60 Q41475564-61C8716D-6D62-4A0A-BEF2-024F4741F96D Q42922883-BF5D329C-9868-4024-AE8A-7C585F34948E Q43379649-16867336-CD1D-4726-92A3-0CFD7386ECEC Q43561521-7D2E9AAD-95A5-4A64-ABC7-32FF57F8A09D Q46539805-95542412-0935-4BD9-8D07-C51EF7A9C486 Q47129111-EA4572C6-0E20-449A-BEC7-6C80CA94AEAF Q47591667-6A38A63B-231B-4ED5-A062-49A4A56AD51A Q48015862-7A256501-DB5A-495B-9420-E7D0A05B66D8 Q48546289-572C4B80-B8A2-4C9D-BABB-F125CCB2D950 Q48714993-6EAFBE7B-265F-4D52-8907-835C5A3288EE Q49413036-C6D30323-5077-455E-A595-1B21DA9456D2 Q50050196-80ACDA10-DB0E-45ED-8872-777FA750801E Q50795251-0259359A-F12B-49B6-B074-307B51A73FFA

P2860

A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117

http://www.wikidata.org/entity/Q33847603

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase I/II radiation dose es ...... : phase I results of RTOG 0117

@ast

A phase I/II radiation dose es ...... : phase I results of RTOG 0117

@en

type

label

A phase I/II radiation dose es ...... : phase I results of RTOG 0117

@ast

A phase I/II radiation dose es ...... : phase I results of RTOG 0117

@en

prefLabel

A phase I/II radiation dose es ...... : phase I results of RTOG 0117

@ast

A phase I/II radiation dose es ...... : phase I results of RTOG 0117

@en

P1433

Q33847603-2CBB732B-CBA9-472C-9306-0FF7711BE837

P1476

Q33847603-B0DB6FC8-0D43-46B1-B401-8C130DDBCD88

P2093

Q33847603-042FF173-A7AF-4AC3-909B-191ADF3630E6

Q33847603-1D46D1C8-A318-453C-A0CD-2528B500B946

Q33847603-2D3064AE-59F0-432D-A7E1-8A75B58EA22E

Q33847603-61327979-021A-4935-93F2-E34AA9C927F0

Q33847603-70DECB12-8C34-4566-B373-F2A6BB93D89F

Q33847603-7EF18DAE-DD32-4E3C-A5DE-B1D9CA79811C

Q33847603-8696C6E9-CB5F-41CE-9474-6E624AB15637

Q33847603-A4281C70-B48A-41F5-BDC4-CE96D5C089C5

Q33847603-A51B4028-95D1-48A5-9F3D-186B644B83D1

Q33847603-BBBA7C43-2397-4A0C-87C6-413C1BDDEBC2

P2860

Q33847603-338D6872-EB41-4277-BB69-CBF5D578FC4C

Q33847603-41624FF1-0C4B-4281-91BA-1AE645170D69

Q33847603-A04F8EBF-10D8-45A1-BC30-21B3DEB5E001

Q33847603-FDEB81C4-82B9-4EA3-9C1B-92630CD134AE

P304

Q33847603-068D21E8-A764-48E5-8F50-BBBA149B509F

P31

Q33847603-190EB663-727B-463E-B56D-F8CBF58101C1

P356

Q33847603-F50FA8AD-B43D-4D80-B411-122D5FEACFFE

P407

Q33847603-5902C4B9-60E4-4D87-939A-7A9A37E2008E

P433

Q33847603-6CDD8374-5452-4E49-A80E-4C51C689712B

P478

Q33847603-F3EA1C86-0C26-47A0-82FF-4AA45555F228

P577

Q33847603-6393E776-883F-44BA-A9CC-EC415DBB6279

P5875

Q33847603-CFF3EA00-2641-42A6-AD3E-55665EBA8597

P698

Q33847603-CF5E4831-A4C7-49C5-BE0F-58AA3EC0B184

P921

Q33847603-22D435DA-2834-4D41-9F0A-6DB510E60807

P932

Q33847603-2F090AE4-00B8-456A-87BA-0C56D2C6402D

P356

J.IJROBP.2009.04.029

P1433

International Journal of Radiation Oncology Biology Physics

P1476

A phase I/II radiation dose es ...... : phase I results of RTOG 0117

@en

P2093

Elizabeth Gore

http://www.w3.org/2001/XMLSchema#string

Hak Choy

http://www.w3.org/2001/XMLSchema#string

Jack Fowler

http://www.w3.org/2001/XMLSchema#string

James A Purdy

http://www.w3.org/2001/XMLSchema#string

Jeff M Michalski

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Bradley

http://www.w3.org/2001/XMLSchema#string

Jennifer Moughan

http://www.w3.org/2001/XMLSchema#string

Mary V Graham

http://www.w3.org/2001/XMLSchema#string

Ramaswamy Govindan

http://www.w3.org/2001/XMLSchema#string

Roger Byhardt

http://www.w3.org/2001/XMLSchema#string

P2860

Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.

Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 S

P304

367-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJROBP.2009.04.029

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44587232

http://www.w3.org/2001/XMLSchema#string

P698

20457350

http://www.w3.org/2001/XMLSchema#string

P921

P932

2869096

http://www.w3.org/2001/XMLSchema#string